Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. is positioned for a strong financial outlook, backed by a successful Phase 3 trial and favorable regulatory conditions that may lead to a re-rating in multiple expansion and heightened commercial success probabilities. The company's peak revenue estimate for 2040 has been adjusted upward to $6.8 billion, reflecting optimism regarding the adoption and market dynamics for its product candidate VAX-31, slated for launch in 2028. Additionally, positive recent clinical data, including superiority results in critical serotypes, enhances investor confidence and suggests a significant market opportunity, particularly with potential recommendations for broader adult usage of pneumococcal conjugate vaccines.

Bears say

Vaxcyte Inc. faces significant challenges that contribute to a negative outlook on its stock, particularly surrounding the anticipated results from its VAX-24 Phase 2 dose-finding trial, which underwhelmed investors amid elevated expectations for the infant pneumococcal conjugate vaccine market. Regulatory pressures and a more stringent vaccine approval environment have created additional headwinds, complicating the commercial viability of its product candidates, especially if national guidelines do not favor their use. Furthermore, the inherent risks of clinical trial outcomes, including potential safety and efficacy failures of its vaccine candidates, add further uncertainty to the company's financial prospects.

Vaxcyte (PCVX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.